FDG PET/CT is now MBS Rebated for work-up of Dementia/Mild Cognitive Impairment
23/11/2021
Early diagnosis and characterization of dementia is a growing challenge in the clinical setting. FDG PET/CT is a highly useful tool for the diagnosis of neurodegenerative disorders. Distinct patterns of altered glucose metabolism seen on FDG PET/CT can improve the clinical diagnosis for differing types of dementia such as FTD, Alzheimer disease and Dementia with Lewy Body.
Case study above: FDG PET fused to MRI brain in patient referred for cognitive impairment work-up at Qscan showing classic findings of Dementia with Lewy Bodies (DLB).
Bilateral parietal and posterior temporal hypometabolism (yellow arrows) like Alzheimer disease (AD). However occipital hypometabolism (preserved in AD) with relative sparing of posterior cingulate cortex gives rise to “cingulate island sign”, highly specific for DLB (star). Also basal ganglia hypermetabolism and an occipital tunnel sign (relative preserved medial occipital metabolism but suppressed lateral occipital lobes) can be seen.
FDG PET for Dementia or Cognitive Impairment is available at all Qscan PET/CT clinics and led by our expert Nuclear Medicine Team.
Dr Peter Jackson
MBBS (UQ) FRANZCR, FAANMS
Special Interests: Nuclear Medicine, PET Imaging & Oncology Imaging
Dr Phillip Law
MBBS (UNSW) FRANZCR, FAANMS
Special Interests: Nuclear Medicine, PET Imaging & Oncology Imaging, Molecular Imaging, Novel Radiotracers & Body Imaging
Dr Gavin Mackle
MBBS, FRANZCR, FAANMS
Special Interests: Nuclear Medicine, PET Imaging & Oncology Imaging
Dr Zeyad Al-Ogaili
MBChB (UQ) FRANZCR, FRCR, FAANMS
Special Interests: Oncology Imaging, PET CT, Nuclear Medicine, Cardiac, Chest & Body Imaging
Dr Kevin Lee
BSc(Med), MBBS MHS (Clin Epi), FRACP
Special Interests: Endocrinology & Nuclear Medicine
Dr Dalveer Singh
BSc(Med), MBBS (Hon 1) FRANZCR, FAANMS
Special Interests: Nuclear Medicine, Molecular Imaging, Theranostic, Oncological Imaging & General Intervention